Jean-Paul Kress, formerly of Biogen Inc and Sanofi Genzyme, is to take over as chief executive of MorphoSys AG on 1 September, succeeding Simon Moroney, the company’s co-founder and CEO. Dr Kress will assume the leadership position just as MorphoSys seeks to register and commercialise its first wholly-owned product tafasitamab for diffuse large B cell lymphoma.
